- Home
- TRUG vs EVAX Comparison
TRUG vs EVAX Comparison
Compare TRUG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- EVAX
- Stock Information
- Founded
- TRUG 1983
- EVAX 2008
- Country
- TRUG United States
- EVAX Denmark
- Employees
- TRUG N/A
- EVAX N/A
- Industry
- TRUG
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRUG
- EVAX Health Care
- Exchange
- TRUG NYSE
- EVAX Nasdaq
- Market Cap
- TRUG 16.2M
- EVAX 16.3M
- IPO Year
- TRUG N/A
- EVAX 2021
- Fundamental
- Price
- TRUG $0.47
- EVAX $2.53
- Analyst Decision
- TRUG Strong Buy
- EVAX Strong Buy
- Analyst Count
- TRUG 1
- EVAX 3
- Target Price
- TRUG $2.00
- EVAX $33.33
- AVG Volume (30 Days)
- TRUG 5.4M
- EVAX 6.8M
- Earning Date
- TRUG 03-04-2025
- EVAX 03-26-2025
- Dividend Yield
- TRUG N/A
- EVAX N/A
- EPS Growth
- TRUG N/A
- EVAX N/A
- EPS
- TRUG N/A
- EVAX N/A
- Revenue
- TRUG $21,917,131.00
- EVAX $3,295,000.00
- Revenue This Year
- TRUG $11.00
- EVAX $9,039.73
- Revenue Next Year
- TRUG $20.54
- EVAX $1.47
- P/E Ratio
- TRUG N/A
- EVAX N/A
- Revenue Growth
- TRUG 7.68
- EVAX N/A
- 52 Week Low
- TRUG $0.35
- EVAX $2.22
- 52 Week High
- TRUG $2.27
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- TRUG 48.97
- EVAX 40.91
- Support Level
- TRUG $0.36
- EVAX $2.43
- Resistance Level
- TRUG $0.67
- EVAX $2.80
- Average True Range (ATR)
- TRUG 0.05
- EVAX 0.31
- MACD
- TRUG 0.01
- EVAX 0.07
- Stochastic Oscillator
- TRUG 31.69
- EVAX 16.94
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.